I am interested in developing new medications for neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia, ADHD, pain, anxiety, and drug addiction. My lab works closely with medicinal chemists to design and test new drug-like molecules, using molecular and behavioral pharmacology methods to evaluate their preclinical potential. Current research targets include the dopamine D4 receptor, dopamine D3 receptor, the mu opioid receptor, and the sigma-1 and sigma-2 receptors.